文献速递泌尿男性生殖肿瘤

根治性膀胱切除术治疗浸润性膀胱癌:1054例患者的长期结果

Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients.
PubMed 文献 · J Clin Oncol · 2023-01-01

该研究评估了1971年7月至1997年12月间接受根治性膀胱切除加双侧盆腔髂淋巴结清扫术的1054例浸润性膀胱癌患者的长期结局。中位随访10.2年,全组5年和10年无复发生存率分别为68%和66%,淋巴结阴性且器官局限肿瘤患者生存率更高,淋巴结阳性患者显著更低。结论支持对浸润性膀胱癌行积极手术治疗,可实现优异的长期生存且盆腔复发率低。

要点

  • 全组1054例患者5年和10年无复发生存率分别为68%和66%。
  • 淋巴结阴性器官局限肿瘤患者5年无复发生存率79%至92%。
  • 淋巴结阳性患者5年和10年无复发生存率分别为35%和34%。

核心结论

  • 来自大样本患者的数据支持对浸润性膀胱癌行积极手术治疗。
  • 可实现优异的长期生存且盆腔复发率低。

研究设计与样本

  • 评估1971年7月至1997年12月间因膀胱移行细胞癌接受根治性膀胱切除加双侧盆腔髂淋巴结清扫术、以治愈为目的、伴或不伴辅助放疗或化疗的所有患者。

主要发现

  • 共1054例患者(843例男性[80%]和211例女性),中位年龄66岁(范围22至93岁),中位随访10.2年(范围0至28年)。
  • 全组5年和10年无复发生存率分别为68%和66%。
  • 淋巴结阴性器官局限肿瘤患者5年和10年无复发生存率:P0期为92%和86%,Pis期为91%和89%,Pa期为79%和74%,P1期为83%和78%。
  • 淋巴结阴性肌层浸润(P2和P3a)肿瘤患者5年和10年无复发生存率分别为89%和87%以及78%和76%。
  • 淋巴结阴性非器官局限(P3b、P4)肿瘤患者复发概率显著高于器官局限膀胱癌患者(P < .001);P3b期5年和10年无复发生存率分别为62%和61%,P4期分别为50%和45%。

关键数值与推荐

  • 246例患者(24%)有淋巴结肿瘤累及,其5年和10年无复发生存率分别为35%和34%,显著低于无淋巴结累及患者(P < .001)。
  • 患者还可按累及淋巴结数目和原发膀胱肿瘤范围(p分期)进行分层;阳性淋巴结少于5个且p分期为器官局限者生存率显著改善。
  • 膀胱癌复发311例(30%);复发患者中位复发时间为12个月(范围0.04至11.1年)。
  • 234例(22%)为远处复发,77例(7%)为局部(盆腔)复发。
  • 27例(2.5%)围手术期死亡,共292例(28%)早期并发症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate our long-term experience with patients treated uniformly with radical cystectomy and pelvic lymph node dissection for invasive bladder cancer and to describe the association of the primary bladder tumor stage and regional lymph node status with clinical outcomes. PATIENTS AND METHODS: All patients undergoing radical cystectomy with bilateral pelvic iliac lymphadenectomy, with the intent to cure, for transitional-cell carcinoma of the bladder between July 1971 and December 1997, with or without adjuvant radiation or chemotherapy, were evaluated. The clinical course, pathologic characteristics, and long-term clinical outcomes were evaluated in this group of patients. RESULTS: A total of 1,054 patients (843 men [80%] and 211 women) with a median age of 66 years (range, 22 to 93 years) were uniformly treated. Median follow-up was 10.2 years (range, 0 to 28 years). There were 27 (2.5%) perioperative deaths, with a total of 292 (28%) early complications. Overall recurrence-free survival at 5 and 10 years for the entire cohort was 68% and 66%, respectively. The 5- and 10-year recurrence-free survival for patients with organ-confined, lymph node-negative tumors was 92% and 86% for P0 disease, 91% and 89% for Pis, 79% and 74% for Pa, and 83% and 78% for P1 tumors, respectively. Patients with muscle invasive (P2 and P3a), lymph node-negative tumors had 89% and 87% and 78% and 76% 5- and 10-year recurrence-free survival, respectively. Patients with nonorgan-confined (P3b, P4), lymph node-negative tumors demonstrated a significantly higher probability of recurrence compared with those with organ-confined bladder cancers (P < .001). The 5- and 10-year recurrence-free survival for P3b tumors was 62% and 61%, and for P4 tumors was 50% and 45% , respectively. A total of 246 patients (24%) had lymph node tumor involvement. The 5- and 10-year recurrence-free survival for these patients was 35%, and 34%, respectively, which was significantly lower than for patients without lymph node involvement (P < .001). Patients could also be stratified by the number of lymph nodes involved and by the extent of the primary bladder tumor (p stage). Patients with fewer than five positive lymph nodes, and whose p stage was organ-confined had significantly improved survival rates. Bladder cancer recurred in 311 patients (30%) . The median time to recurrence among those patients in whom the cancer recurred was 12 months (range, 0.04 to 11.1 years). In 234 patients (22%) there was a distant recurrence, and in 77 patients (7%) there was a local (pelvic) recurrence. CONCLUSION: These data from a large group of patients support the aggressive surgical management of invasive bladder cancer. Excellent long-term survival can be achieved with a low incidence of pelvic recurrence.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Stein JP, Lieskovsky G, Cote R, et al. Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients. J Clin Oncol. 2023. PMID: 37499357. doi:10.1200/JCO.22.02762

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。